Join a Clinical Trial

Research

The Anand Spine Group is strongly committed to ongoing clinical research throughout the practice.

Clinical Trials

Two-Level Synergy Cervical Disc Replacement Trial

The Anand Spine Group is currently enrolling patients for a Food and Drug Administration (FDA) Investigational Device Exemption study focused on the treatment of two-level symptomatic cervical degenerative disc disease (DDD). Sponsored by Synergy Spine Solutions Inc., the clinical trial's purpose is to demonstrate that the Synergy Disc is at least as safe and effective as conventional anterior cervical discectomy and fusion to treat cervical DDD at two levels between C3 and C7. To find out if you are eligible for this trial, contact the office at (310) 423-9779 and make an appointment to meet with Dr. Anand.

Eligibility

Key Inclusion Criteria

  • 18-69 years old
  • Must demonstrate:
    • Diagnosis of cervical radiculopathy or myelopathy with radiculopathy
    • Symptomatic cervical disc disease at two contiguous levels, C3 to C7
    • Decreased disc height, degenerative spondylosis, or disc herniation
  • At least six weeks of failed conservative
    treatment prior to surgery

 

Key Exclusion Criteria

  • More than two levels of symptomatic cervical disc disease
  • History of spine surgery at the operative levels
  • Less than 3 mm of disc height at the index levels
  • Marked cervical instability at the  index levels

TOPS System Trial

Dr. Anand is the Principal Investigator for the FDA Investigational Device Exemption Application for the Clinical Investigation of the TOPS System. The TOPS System is a motion-preserving surgical procedure designed to decompress and stabilize a spine segment, rather than fuse the segment. The trial compares the safety and effectiveness of the TOPS System to a lumbar fusion. To find out if you are eligible for this trial, contact the office at (310) 423-9779 and make an appointment to meet with Dr. Anand.

Eligibility

Key Inclusion Criteria

  • 35-80 years old
  • Must demonstrate:
    • Degenerative spondylolisthesis or retrolisthesis up to Grade 1
    • At least moderate lumbar spinal stenosis
    • Thickening of the ligamentum flavum and/or scarring of the facet joint capsule
  • At least six months of failed conservative
    treatment prior to surgery

 

Key Exclusion Criteria

-More than one motion segment involved in the degenerative pathology that requires a surgical procedure

- Presence of free fragment disc herniation at the index level or

- Less than 4 mm of disc height at the index level

STRUCTURE Study

Dr. Anand is the Principal Investigator for the FDA Investigational Device Exemption study focusing on individuals who have been diagnosed with degenerative disc disease and require surgery to prevent the damaged disc from moving (which would decrease associated pain). During this type of surgery, the damaged disc is removed, and the vertebras are fused together by inserting a device with a bone graft to help stabilize the spine during the healing process (a procedure called spinal fusion).

The purpose of this study is to examine the safety and effectiveness of an investigational drug called KUR-113 Bone Graft (compared to a local autograft) as a possible treatment for patients with degenerative disc disease who will undergo surgery for spinal fusion. Researchers aim to determine how well the drug works, which dose is most effective, and how safe it is compared to standard surgical treatment using a local graft.

 
To find out if you are eligible for this trial, contact the office at (310) 423-9779 and make an appointment to meet with Dr. Anand. Health insurance is required. 

Eligibility

Key Inclusion Criteria

  • 25-75 years old (Females of childbearing potential must not be pregnant and must agree to use acceptable contraception for at least 12 months after surgery and investigational product placement.)
  • Patients with degenerative disc disease with up to grade 1 spondylolisthesis and leg pain requiring up to 3 levels of laminectomy/decompression and single-level fusion
  • Patients with an Oswestry Disability Index score ≥35

 

Key Exclusion Criteria

  • Patients with open epiphyseal plates (layer of cartilage)
  • Requiring emergency spinal decompression or spinal fusion
  • Requiring multilevel fusion or expected to need secondary intervention within one year following surgery